BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Käräjämäki AJ, Hukkanen J, Kauma H, Kesäniemi YA, Ukkola O. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020;80:106-13. [PMID: 31851849 DOI: 10.1080/00365513.2019.1700428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Varadharajan V, Massey WJ, Brown JM. Membrane-Bound O-Acyltransferase 7 (MBOAT7) Driven Phosphatidylinositol Remodeling in Advanced Liver Disease. Journal of Lipid Research 2022. [DOI: 10.1016/j.jlr.2022.100234] [Reference Citation Analysis]
2 Yang H, Deng Q, Ni T, Liu Y, Lu L, Dai H, Wang H, Yang W. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. Int J Biol Sci 2021;17:4207-22. [PMID: 34803493 DOI: 10.7150/ijbs.64714] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
3 Feng X, Li W, Cheng M, Qiu W, Liang R, Li M, Chen W, Wang D. Association of hearing loss with total and cause-specific mortality in US adults. Environ Sci Pollut Res Int 2021. [PMID: 34414544 DOI: 10.1007/s11356-021-16038-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 2021. [PMID: 34324263 DOI: 10.1111/dom.14484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
5 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. Int J Mol Sci 2021;22:6949. [PMID: 34203309 DOI: 10.3390/ijms22136949] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
7 Raimi TH, Dele-Ojo BF, Dada SA, Fadare JO, Ajayi DD, Ajayi EA, Ajayi OA. Triglyceride-Glucose Index and Related Parameters Predicted Metabolic Syndrome in Nigerians. Metab Syndr Relat Disord 2021;19:76-82. [PMID: 33170086 DOI: 10.1089/met.2020.0092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
8 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
9 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. Ann Hepatol 2021;21:100260. [PMID: 32987175 DOI: 10.1016/j.aohep.2020.09.004] [Reference Citation Analysis]
10 Ismaiel A, Dumitrascu DL. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review. Eur J Clin Invest 2020;50:e13331. [PMID: 32589269 DOI: 10.1111/eci.13331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
11 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]